Please login to the form below

Not currently logged in
Email:
Password:

Konstantin Linnik to head IP strategy at Idea Pharma

Former senior corporate counsel at Pfizer joins clinical stage strategy consultancy as general counsel and principal IP strategist

Konstantin Linnik - Idea PharmaIdea Pharma has appointed former senior corporate counsel at Pfizer Konstantin Linnik as its general counsel and principal intellectual property (IP) strategist.

Idea, which specialises in advising a company's strategy at the phase II stage of development, said Linnink will lead IP inputs into whole product design, giving insight into the potential opportunities for early phase assets and advising on how to improve developmental products.

The appointment is also expected to expand Idea's portfolio of clients to medium-sized pharma companies, and also give the company a base in Boston, US.

Linnik, who will join from Boston law firm Nutter McClennen and Fish LLP, said Idea's focus on distinct elements such as IP during early phase development influenced his decision to join the company.

He said: “A small change in product concept, that produces a better medicine, one with even six months more protection, can make billions of dollars difference over the lifecycle.”

Mike Rea, CEO of Idea, said: “The fantastic thing about Konstantin is that he gets it - that the role of invention isn't over when someone comes up with a pathway and a molecule.”

20th December 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics